Upstream Bio Inc. reported additional analyses from its Phase 2 VIBRANT trial (NCT06164704) evaluating verekitug in 81 adults with chronic rhinosinusitis with nasal polyps over 24 weeks. The new analyses adjusted for concomitant rescue therapy use using a worst-observation carried-forward approach and showed a placebo-adjusted reduction in endoscopic nasal polyp score of -1.95 (p < 0.0001) and a reduction in nasal congestion score of -0.96 (p < 0.0001) at week 24; the company also reiterated previously reported data showing a 76% reduction in the need for surgery or systemic corticosteroids versus placebo (p = 0.03). These additional results were presented at the AAAAI 2026 Annual Meeting, and the company said planning has begun for Phase 3 trials in chronic rhinosinusitis with nasal polyps and severe asthma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Upstream Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603010945PRIMZONEFULLFEED9663439) on March 01, 2026, and is solely responsible for the information contained therein.